Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Joaquin Bellmunt Molins, M.D.

Co-Author

This page shows the publications co-authored by Joaquin Bellmunt Molins and Guru Sonpavde.
Connection Strength

12.359
  1. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 08; 16(4):e961-e967.
    View in: PubMed
    Score: 0.775
  2. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU Int. 2017 04; 119(4):579-584.
    View in: PubMed
    Score: 0.702
  3. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 12; 14(6):494-498.
    View in: PubMed
    Score: 0.680
  4. Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol. 2016 06; 13(6):306-7.
    View in: PubMed
    Score: 0.676
  5. Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business? Eur Urol. 2016 Apr; 69(4):574-575.
    View in: PubMed
    Score: 0.654
  6. Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):644-645.
    View in: PubMed
    Score: 0.651
  7. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. 2016 Feb; 195(2):277-82.
    View in: PubMed
    Score: 0.646
  8. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):634-641.
    View in: PubMed
    Score: 0.645
  9. Precision and predictive medicine in urothelial cancer: are we making progress? Eur Urol. 2015 Oct; 68(4):547-9.
    View in: PubMed
    Score: 0.633
  10. Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change? Oncologist. 2015 May; 20(5):461-3.
    View in: PubMed
    Score: 0.630
  11. Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU Int. 2015 Jun; 115(6):854-5.
    View in: PubMed
    Score: 0.621
  12. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr; 13(2):185-92.
    View in: PubMed
    Score: 0.608
  13. A new approach to second-line therapy for urothelial cancer? Lancet Oncol. 2013 Jul; 14(8):682-4.
    View in: PubMed
    Score: 0.553
  14. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23.
    View in: PubMed
    Score: 0.535
  15. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018 12; 200(6):1207-1214.
    View in: PubMed
    Score: 0.200
  16. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
    View in: PubMed
    Score: 0.171
  17. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2017 02; 15(1):23-30.e2.
    View in: PubMed
    Score: 0.170
  18. Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):361-76, x.
    View in: PubMed
    Score: 0.154
  19. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer. 2015 Jun; 13(3):250-6.
    View in: PubMed
    Score: 0.153
  20. Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer. 2015 Apr; 13(2):178-84.
    View in: PubMed
    Score: 0.152
  21. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec; 12(6):395-8.
    View in: PubMed
    Score: 0.149
  22. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb; 13(1):71-9.
    View in: PubMed
    Score: 0.149
  23. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
    View in: PubMed
    Score: 0.148
  24. New agents for prostate cancer. Ann Oncol. 2014 Sep; 25(9):1700-1709.
    View in: PubMed
    Score: 0.146
  25. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):130-7.
    View in: PubMed
    Score: 0.142
  26. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer. 2013 Dec; 11(4):495-500.
    View in: PubMed
    Score: 0.139
  27. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013 Jul; 87(1):80-9.
    View in: PubMed
    Score: 0.135
  28. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012 Aug; 14(4):295-306.
    View in: PubMed
    Score: 0.131
  29. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
    View in: PubMed
    Score: 0.129
  30. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8.
    View in: PubMed
    Score: 0.120
  31. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012 Feb; 23(2):406-10.
    View in: PubMed
    Score: 0.120
  32. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol. 2011 Aug; 60(2):270-8.
    View in: PubMed
    Score: 0.120
  33. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4.
    View in: PubMed
    Score: 0.119
  34. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 04 15; 25(8):2458-2470.
    View in: PubMed
    Score: 0.051
  35. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2019 02 15; 125(4):533-540.
    View in: PubMed
    Score: 0.051
  36. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018 05; 118(11):1434-1441.
    View in: PubMed
    Score: 0.049
  37. Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 09 28; 5(1):80.
    View in: PubMed
    Score: 0.047
  38. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 08 15; 5(1):68.
    View in: PubMed
    Score: 0.046
  39. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clin Genitourin Cancer. 2017 10; 15(5):509-512.e9.
    View in: PubMed
    Score: 0.045
  40. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. Eur Urol Focus. 2018 12; 4(6):937-945.
    View in: PubMed
    Score: 0.045
  41. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318.
    View in: PubMed
    Score: 0.045
  42. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 02; 71(2):281-289.
    View in: PubMed
    Score: 0.044
  43. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr; 69(4):624-633.
    View in: PubMed
    Score: 0.041
  44. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016 Jan; 27(1):49-61.
    View in: PubMed
    Score: 0.041
  45. Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep. 2013 Jun; 14(3):174-83.
    View in: PubMed
    Score: 0.035
  46. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012 Dec; 13(13):1676-86.
    View in: PubMed
    Score: 0.033
  47. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.